Evidence map›Paper›PMID 42165713›Full record

ArticleThe Indian journal of medical research2026

E-protein variability in Zika virus strains: A possible new O-glycosylation site and its implications.

Lokesh Kori, Anshuman Chandra, Labanya Mukhopadhyay, Kanika Verma, Nivedita Gupta

Abstract read
In one paragraph

Article in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lokesh KoriDivision of Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
Anshuman ChandraSchool of Physical Science, Jawaharlal Nehru University, New Delhi, India.
Labanya MukhopadhyayDivision of Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
Kanika VermaDepartment of Molecular Epidemiology, ICMR-National Institute of Malaria Research, New Delhi, India.
Nivedita GuptaDivision of Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives Zika virus (ZIKV) is a flavivirus transmitted by the bite of infected Aedes mosquito. In 2015-16, Brazil reported cases of ZIKV virus infection followed by Guillain-Barre syndrome and congenital birth defects. India has reported ZIKV virus infections sporadically since 2016, without adverse events. This prompted us to conduct this in-silico investigation and identify reasons for this variation. The objective was to study ZIKV envelope protein (E-protein) to identify possible mutations and their potential role in virus entry into the host cell. Methods Using multiple sequence alignments, we compared the genomic sequences from eleven ZIKV strains with maximum genomic data available in the NCBI database, followed by phylogenetic analysis. ZIKV E-protein structures with mutations were generated using AlphaFold and used for molecular dynamic simulation, followed by protein 3D structure and residues interaction analysis. Results We identified 2 major ZIKV clades - ZIKV Senegal strain (African lineage, Accession No. MF510857, 1984) is an ancestral strain representing one clade, while the remaining strains belong to the second major clade, with the Indian strain being closest to the Senegal strain genomically. The Senegal strain also has a significant mutation at residue no. 120 of the E-protein (Alanine to Threonine), which is absent in other strains. Interpretation and conclusions We found a mutation in the ZIKV Senegal strain at residue no. 120 (Alanine Threonine), here Threonine is interacting with Serine residue at position 64. This interaction is known for post-translational O-glycosylation of E-protein, which may reduce the efficacy of envelope-based therapies. To the best of our knowledge, this is the first report of a putative O-glycosylation site on the E-protein of a ZIKV strain, which is an important therapeutic target, and our finding needs further in vitro validation.

Indexed as

Viral Envelope ProteinsZika VirusZika Virus InfectionAedesAnimalsBrazilGlycosylationHumansIndiaMolecular Dynamics SimulationMutationPhylogenyViral Envelope ProteinsE-proteinFlavivirusO-glycosylationVector borne diseasesZika virus

Identifiers

PMID42165713
PMCPMC13224298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.